Arcus Biosciences Inc., a clinical-stage global biopharmaceutical company, has announced new employment inducement grants for two new employees. The grants include options to purchase a total of 13,400 shares of the company's common stock at an exercise price of $9.02 per share, reflecting the closing price on May 23, 2025. Additionally, the employees were awarded restricted stock units to acquire a total of 13,400 shares of the company's common stock. These equity awards are part of the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under the NYSE's inducement exception rule.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。